Legal Representation
Attorney
Kristen S. Ruisi
USPTO Deadlines
Next Deadline
1013 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20220927)
Due Date
September 27, 2028
Grace Period Ends
March 27, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
43 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 29, 2025 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Oct 29, 2025 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Jul 10, 2025 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Jul 9, 2025 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | Loading... |
| Mar 24, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Mar 24, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Mar 24, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Dec 8, 2022 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Dec 8, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Dec 8, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Dec 8, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Dec 8, 2022 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Sep 27, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Sep 27, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Aug 23, 2022 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Aug 22, 2022 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Aug 19, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 18, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 18, 2022 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Aug 11, 2022 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Aug 11, 2022 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Aug 11, 2022 | CNFR | W | SU - FINAL REFUSAL - WRITTEN | Loading... |
| Jul 12, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 12, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 11, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 7, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 7, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 7, 2022 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| Jun 1, 2022 | DMCC | I | DATA MODIFICATION COMPLETED | Loading... |
| Jun 1, 2022 | ALIE | A | ASSIGNED TO LIE | Loading... |
| May 26, 2022 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| May 12, 2022 | IUAF | S | USE AMENDMENT FILED | Loading... |
| May 26, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| May 12, 2022 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Dec 14, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 19, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 19, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 29, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 13, 2021 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 8, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 23, 2021 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Jul 22, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 19, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemico-pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; drugs in the nature of pharmaceutical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for pharmaceutical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; medicines for human purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Injectable pharmaceuticals for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; crude drugs in the nature of pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Biochemical preparations for medical use for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases
First Use Anywhere:
Sep 20, 2021
First Use in Commerce:
Sep 20, 2021
Class 040
Custom manufacturing services in the nature of chemical processing and production of medicines and pharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases
First Use Anywhere:
Sep 20, 2021
First Use in Commerce:
Sep 20, 2021
Class 042
Research and development of new products for others; technological research in the field of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical research; conducting clinical trials for others for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological research; quality control for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; electronic data storage; material testing; cloud computing featuring software for use in database management, word processing, spreadsheet management, tracking; packaging design
First Use Anywhere:
Sep 20, 2021
First Use in Commerce:
Sep 20, 2021
Class 044
Telemedicine services; health care; convalescent home services; physical therapy services; health counseling; pharmacy advice, namely, pharmaceutical advice
First Use Anywhere:
Sep 20, 2021
First Use in Commerce:
Sep 20, 2021
Additional Information
Design Mark
The mark consists of a shaded square in red with a stylized red square and a star cutout in the center of the stylized square to the left of the black wording "BeiGene" with a red arrow as part of the letter "G.
Color Claim
The color(s) red and black is/are claimed as a feature of the mark.
Classification
International Classes
005
040
042
044